Experimental radiation therapy shows success in late-stage tumor trial

Bristol Myers Squibb reported positive Phase 3 results for RYZ101, a radiopharmaceutical targeting rare neuroendocrine tumors. The treatment delivers targeted radiation directly to cancer cells to disrupt their DNA structure while protecting healthy tissue.